Vanda Pharmaceuticals
Washington D.C., District of Columbia, 20037, United States
Location status: Recruiting
NCT Number: NCT01195558
Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.
Interested in participating?
Request InfoAll sexes
Observational
Washington D.C., District of Columbia, 20037, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
Other names: Data Collection
Time frame: ongoing
Time frame: ongoing
Contact information is provided by the study sponsor or research team.
Vanda Pharmaceuticals
Industry
Development of a Patient Registry of Blind Subjects With Sleep-related Problems
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07482176
Blindness, Eye Diseases
Mesa, Arizona, United States
View Trial DetailsNCT03011541
Abnormalities, Multiple, Age-Related Macular Degeneration
Westport, Connecticut, United States
View Trial DetailsNCT06891443
Blindness, Congenital Abnormalities
San Francisco, California, United States
View Trial DetailsNCT07630649
Blindness, Eye Diseases
Deerfield Beach, Florida, United States
View Trial Details